BSE filing, NSE: AFFLE. Summary written from the filing by ALFA Finder's alert engine.
Affle 3I Ltd: key numbers
- Share price
- ₹1,416.10
- Market cap
- ₹20,377 Cr
- Revenue (annual)
- ₹2,709 Cr
- Net profit (annual)
- ₹454.9 Cr
- P/E (TTM)
- 42.6×Sector 23.0×
- Promoter holding
- 55.42%+0.51% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Affle 3I Ltd
All →Affle 3I Board Meeting Date
Affle 3i will hold a board meeting on 30 October 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. This is a prior intimation, so the results are not yet approved.
Affle 3I Preferential Issue
Affle 3i converted 12,77,155 warrants into equity shares at ₹1,487 per share. The allotment raises approximately ₹189.91 Crore from a single investor.
- Value
- ₹189.9 Cr
Affle 3I Convertible Warrants
Affle 3i converted 17,04,324 warrants into equity shares at ₹836.44 per share. The allotment raised ₹14.26 Crore from one investor.
- Value
- ₹14.26 Cr
Affle 3I Convertible Warrants
Affle 3I allotted 17,04,324 shares to promoter Affle Holdings on warrant conversion at ₹1,115.25 each. The deal adds ~₹190 Crore to paid-up capital.
- Value
- ₹190.1 Cr
Affle 3I Insolvency Petition
Affle 3i Limited announced that the Hon’ble Supreme Court has granted a stay on the CIRP proceedings pending before the NCLT regarding its investment in Bobble.
Affle 3I Convertible Warrants
Affle 3i Limited received USD 34.99 million (approximately Rs. 332.51 Crore) from its promoter, Affle Holdings Pte. Ltd. This payment is for the exercise of convertible warrants into equity shares.
- Value
- ₹332.5 Cr
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.